At Elite Research Labs, researchers can review third-party verified Retatrutide research peptide supported by batch-specific laboratory testing documentation
Why Menopausal Women Might Consider GLP-1s for Weight Loss Among the unwelcome symptoms of perimenopause (the hormonally turbulent years before periods stop) and menopause, one rises to the top for many women: weight gain
Always discard visibly discolored or cloudy medication and report any unusual symptoms to your healthcare provider immediately
Retatrutide is not yet approved by Health Canada or the FDA
*Contraindications weight loss injections include a personal or family history of medullary thyroid cancer, allergy to GLP-1 and weight loss injections, Type 1 Diabetes or history of Diabetic Ketoacidosis, personal or family history of Multiple Endocrine Neoplasia, personal history of Pancreatitis, renal impairment or kidney disease, gallbladder disease, or concurrent use of anti-diabetic medications or insulin
Supplied as a clean lyophilized research vial for controlled laboratory preparation and storage workflows